{"altmetric_id":16842712,"counts":{"readers":{"mendeley":17,"citeulike":0,"connotea":0},"total":{"posts_count":20},"news":{"unique_users_count":1,"unique_users":["the_asco_post"],"posts_count":1},"twitter":{"unique_users_count":15,"unique_users":["gedefo_sefh","DrRaulCordoba","queizan","chanyooncheah","CGuindel","FarmaOnco","JCO_ASCO","OncInfo","SCTNB","HemSandoval","FrancescoTurtu1","AndreGoyMD","suepomp","JediPD","timfenske"],"posts_count":19}},"selected_quotes":["Late Relapse of Classical Hodgkin Lymphoma: German Hodgkin Study Group. About 5% relapse betw year 5-20. JCO","Late relapse of classical Hodgkin lymphoma: an analysis of German Hodgkin Study Group trials HD7-HD12","Even in early-stage favorable #Hodgkin #Lymphoma, regular clinical follow-up is recommended for timely detection of Late\u2026","Late Relapse of Classical Hodgkin #Lymphoma: Analysis of the German Hodgkin study group HD7 to HD12 trials","Further evidence of linear increased Late Relapses (6.9% @ 20 yrs) in Hodgkin associated with cell-type switch."],"citation":{"abstract":"Purpose Clinical characteristics, therapeutic approaches, and prognosis of late relapse (LR) in patients with classic Hodgkin lymphoma (cHL) are poorly understood. We performed a comprehensive analysis of LR of Hodgkin lymphoma (LR-HL). Methods To estimate the incidence of LR-HL, we retrospectively analyzed 6,840 patients with cHL included in the German Hodgkin Study Group trials HD7 to HD12. Patients who experienced a relapse > 5 years into remission were compared with patients in continued remission for > 5 years and with those who experienced a relapse \u2264 5 years after first diagnosis. Results With a median observation time of 10.3 years, 141 incidences of LR-HL were observed. Cumulative incidences at 10, 15, and 20 years rose linearly and were 2.5%, 4.3%, and 6.9%, respectively. The standardized incidence ratio for HL with respect to age- and sex-matched German reference data was 84.5 (95% CI, 71.2 to 99.7). LR-HL was more frequently observed in patients with early-stage favorable than unfavorable or advanced stage at first diagnosis (15-year cumulative incidence, 5.3% v 3.9% and 3.9%, respectively; P = .01). Overall survival from first diagnosis was worse after LR compared with nonrelapse survivors (10-year estimate, 95.8% v 86.1%; hazard ratio, 2.5; 95% CI, 1.7 to 3.5; P < .001). In patients with LR-HL, survival was better compared with 466 patients with earlier relapse (hazard ratio, 0.6; 95% CI, 0.4 to 0.9, P = .01). Forty-four percent and 49% of patients with LR-HL and earlier relapse, respectively, received stem cell transplantations. Conclusion Apart from treatment-associated adverse effects, survivors after initially successful therapy for cHL are at an 85-fold risk for recurrence of disease compared with the general German population. After risk-adapted treatment strategies, especially in early-stage favorable HL, regular clinical follow-up is recommended for timely detection of LR-HL. With adequate treatment, prognosis of LR-HL is better compared with early relapses.","altmetric_jid":"4f6fa5e93cf058f610005a18","authors":["Paul J. Br\u00f6ckelmann","Helen Goergen","Charlotte Kohnhorst","Bastian von Tresckow","Alden Moccia","Jana Markova","Julia Meissner","Andrea Kerkhoff","Wolf-Dieter Ludwig","Michael Fuchs","Peter Borchmann","Andreas Engert"],"doi":"10.1200\/jco.2016.71.3289","first_seen_on":"2017-02-28T05:12:54+00:00","funders":["niehs"],"issns":["0732-183X","1527-7755"],"journal":"Journal of Clinical Oncology","last_mentioned_on":1495491079,"links":["http:\/\/ascopubs.org\/doi\/abs\/10.1200\/JCO.2016.71.3289?af=R","https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28240973","http:\/\/ascopubs.org\/doi\/abs\/10.1200\/JCO.2016.71.3289?af=R&","http:\/\/ascopubs.org\/doi\/abs\/10.1200\/JCO.2016.71.3289","https:\/\/www.ncbi.nlm.nih.gov\/m\/pubmed\/28240973\/","http:\/\/ascopubs.org\/doi\/full\/10.1200\/JCO.2016.71.3289"],"pmid":"28240973","pubdate":"2017-02-28T13:37:37+00:00","publisher":"American Society of Clinical Oncology (ASCO)","publisher_subjects":[{"name":"Oncology And Carcinogenesis","scheme":"era"}],"scopus_subjects":["Health Sciences","Medicine","Life Sciences","Biochemistry, Genetics and Molecular Biology"],"subjects":["neoplasms"],"title":"Late Relapse of Classical Hodgkin Lymphoma: An Analysis of the German Hodgkin Study Group HD7 to HD12 Trials","type":"article","mendeley_url":"http:\/\/www.mendeley.com\/research\/late-relapse-classical-hodgkin-lymphoma-analysis-german-hodgkin-study-group-hd7-hd12-trials"},"altmetric_score":{"score":15.85,"score_history":{"1y":15.85,"6m":15.85,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":15.85},"context_for_score":{"all":{"total_number_of_other_articles":8250529,"mean":6.9707556030289,"rank":537797,"this_scored_higher_than_pct":93,"this_scored_higher_than":7711908,"rank_type":"exact","sample_size":8250529,"percentile":93},"similar_age_3m":{"total_number_of_other_articles":240873,"mean":13.688962403268,"rank":28525,"this_scored_higher_than_pct":88,"this_scored_higher_than":212301,"rank_type":"exact","sample_size":240873,"percentile":88},"this_journal":{"total_number_of_other_articles":8848,"mean":14.607374477224,"rank":1664,"this_scored_higher_than_pct":81,"this_scored_higher_than":7180,"rank_type":"exact","sample_size":8848,"percentile":81},"similar_age_this_journal_3m":{"total_number_of_other_articles":276,"mean":40.617687272727,"rank":129,"this_scored_higher_than_pct":53,"this_scored_higher_than":147,"rank_type":"exact","sample_size":276,"percentile":53}}},"demographics":{"poster_types":{"member_of_the_public":9,"researcher":1,"practitioner":4,"science_communicator":1},"users":{"twitter":{"cohorts":{"Members of the public":9,"Practitioners (doctors, other healthcare professionals)":4,"Scientists":1,"Science communicators (journalists, bloggers, editors)":1}},"mendeley":{"by_status":{"Professor > Associate Professor":1,"Librarian":1,"Researcher":6,"Student  > Doctoral Student":2,"Student  > Ph. D. Student":2,"Student  > Postgraduate":1,"Other":3,"Student  > Bachelor":1},"by_discipline":{"Medicine and Dentistry":15,"Agricultural and Biological Sciences":2}}},"geo":{"twitter":{"ES":2,"AU":1,"CA":1,"US":5},"mendeley":{"US":1,"GB":1,"DE":1}}},"posts":{"twitter":[{"url":"http:\/\/twitter.com\/gedefo_sefh\/statuses\/836443987519148032","license":"gnip","citation_ids":[16842712],"posted_on":"2017-02-28T05:12:41+00:00","author":{"name":"GEDEFO","url":"http:\/\/www.sefh.es","image":"https:\/\/pbs.twimg.com\/profile_images\/378800000753799388\/8561701cfcfbc3a7efa7ec153101b2ab_normal.jpeg","description":"Grupo de Farmacia Oncol\u00f3gica de la SEFH","id_on_source":"gedefo_sefh","tweeter_id":"2184775389","geo":{"lt":39.5,"ln":-3,"country":"ES"},"followers":2004},"tweet_id":"836443987519148032"},{"url":"http:\/\/twitter.com\/DrRaulCordoba\/statuses\/836451783274823680","license":"gnip","citation_ids":[16842712],"posted_on":"2017-02-28T05:43:40+00:00","author":{"name":"Raul Cordoba","url":"http:\/\/www.fjd.es","image":"https:\/\/pbs.twimg.com\/profile_images\/817087500850229248\/LRpwr7_9_normal.jpg","description":"\ud83c\uddea\ud83c\uddf8Mi Vocaci\u00f3n? La Medicina. Mi Pasi\u00f3n? La Hematolog\u00eda. Mi especialidad? Los Linfomas \ud83c\uddfa\ud83c\uddf8Doctor. Hematologist. Interest in #lymphoma #CLL #gerionc #ImmunoOnc","id_on_source":"DrRaulCordoba","tweeter_id":"1697360292","geo":{"lt":40.42526,"ln":-3.69063,"country":"ES"},"followers":2003},"tweet_id":"836451783274823680"},{"url":"http:\/\/twitter.com\/queizan\/statuses\/836534579557240832","license":"gnip","rt":["DrRaulCordoba"],"citation_ids":[16842712],"posted_on":"2017-02-28T11:12:40+00:00","author":{"name":"Dr. Jos\u00e9 A. Queiz\u00e1n","image":"https:\/\/pbs.twimg.com\/profile_images\/805313113016799232\/jBSTAjA7_normal.jpg","description":"Medico Especialista en Hematologia y Hemoterapia","id_on_source":"queizan","tweeter_id":"2334315479","geo":{"lt":null,"ln":null},"followers":403},"tweet_id":"836534579557240832"},{"url":"http:\/\/twitter.com\/chanyooncheah\/statuses\/836570745954156544","license":"gnip","citation_ids":[16842712],"posted_on":"2017-02-28T13:36:23+00:00","author":{"name":"Chan Cheah","url":"https:\/\/www.researchgate.net\/profile\/Chan_Cheah","image":"https:\/\/pbs.twimg.com\/profile_images\/809022062425583616\/JRnYtLn8_normal.jpg","description":"Haematologist & Clinical Researcher, Sir Charles Gairdner Hospital, Hollywood Private Hospital & University of Western Australia. Lymphoma specialist.","id_on_source":"chanyooncheah","tweeter_id":"245607411","geo":{"lt":-31.95224,"ln":115.8614,"country":"AU"},"followers":298},"tweet_id":"836570745954156544"},{"url":"http:\/\/twitter.com\/gedefo_sefh\/statuses\/836634221716377600","license":"gnip","rt":["DrRaulCordoba"],"citation_ids":[16842712],"posted_on":"2017-02-28T17:48:37+00:00","author":{"name":"GEDEFO","url":"http:\/\/www.sefh.es","image":"https:\/\/pbs.twimg.com\/profile_images\/378800000753799388\/8561701cfcfbc3a7efa7ec153101b2ab_normal.jpeg","description":"Grupo de Farmacia Oncol\u00f3gica de la SEFH","id_on_source":"gedefo_sefh","tweeter_id":"2184775389","geo":{"lt":39.5,"ln":-3,"country":"ES"},"followers":2004},"tweet_id":"836634221716377600"},{"url":"http:\/\/twitter.com\/CGuindel\/statuses\/836719458903277569","license":"gnip","rt":["gedefo_sefh"],"citation_ids":[16842712],"posted_on":"2017-02-28T23:27:19+00:00","author":{"name":"Conchi Guindel","image":"https:\/\/pbs.twimg.com\/profile_images\/616991246305894401\/q2boVw2j_normal.jpg","id_on_source":"CGuindel","tweeter_id":"341720785","geo":{"lt":null,"ln":null},"followers":140},"tweet_id":"836719458903277569"},{"url":"http:\/\/twitter.com\/FarmaOnco\/statuses\/836808452517265409","license":"gnip","rt":["DrRaulCordoba"],"citation_ids":[16842712],"posted_on":"2017-03-01T05:20:56+00:00","author":{"name":"FarmaOnco","image":"https:\/\/pbs.twimg.com\/profile_images\/2930931336\/c5ed1efcf9ddf36d4803c1ab88604f4f_normal.jpeg","description":"Farmac\u00e9utica hospitalaria que intenta mantenerse al d\u00eda en onco, hemato y otras cosas","id_on_source":"FarmaOnco","tweeter_id":"917639060","geo":{"lt":null,"ln":null},"followers":1681},"tweet_id":"836808452517265409"},{"url":"http:\/\/twitter.com\/FarmaOnco\/statuses\/836808818344460288","license":"gnip","rt":["gedefo_sefh"],"citation_ids":[16842712],"posted_on":"2017-03-01T05:22:24+00:00","author":{"name":"FarmaOnco","image":"https:\/\/pbs.twimg.com\/profile_images\/2930931336\/c5ed1efcf9ddf36d4803c1ab88604f4f_normal.jpeg","description":"Farmac\u00e9utica hospitalaria que intenta mantenerse al d\u00eda en onco, hemato y otras cosas","id_on_source":"FarmaOnco","tweeter_id":"917639060","geo":{"lt":null,"ln":null},"followers":1681},"tweet_id":"836808818344460288"},{"url":"http:\/\/twitter.com\/JCO_ASCO\/statuses\/837769880782966784","license":"gnip","citation_ids":[16842712],"posted_on":"2017-03-03T21:01:19+00:00","author":{"name":"J Clinical Oncology","url":"http:\/\/JCO.org","image":"https:\/\/pbs.twimg.com\/profile_images\/715981880357683201\/8GMeAgKJ_normal.jpg","description":"Journal of Clinical Oncology is the authoritative resource for significant oncology research, published 3 times per month by @ASCO.","id_on_source":"JCO_ASCO","tweeter_id":"2395900849","geo":{"lt":null,"ln":null},"followers":6833},"tweet_id":"837769880782966784"},{"url":"http:\/\/twitter.com\/OncInfo\/statuses\/837771056802856960","license":"gnip","rt":["JCO_ASCO"],"citation_ids":[16842712],"posted_on":"2017-03-03T21:05:59+00:00","author":{"name":"Oncology Information","url":"http:\/\/www.oncinfo.ca","image":"https:\/\/pbs.twimg.com\/profile_images\/808392475115130880\/9mmGiVfB_normal.jpg","description":"Oncology Information is a leading service provider for digital solutions aimed at oncology health care providers worldwide","id_on_source":"OncInfo","tweeter_id":"808391089224880129","geo":{"lt":null,"ln":null},"followers":186},"tweet_id":"837771056802856960"},{"url":"http:\/\/twitter.com\/SCTNB\/statuses\/837783727384236033","license":"gnip","rt":["JCO_ASCO"],"citation_ids":[16842712],"posted_on":"2017-03-03T21:56:20+00:00","author":{"name":"Dr T. Comeau , MD","image":"https:\/\/pbs.twimg.com\/profile_images\/378800000365246082\/373bc9bced36e8f90f0d52d727fc6b34_normal.jpeg","description":"Director New Brunswick Stem Cell Transplant Program ; SCT Physician ; #hematology: #leukemia, #MDS, #lymphoma, #mmsm , #apheresis, #bmtsm , #immunotherapy","id_on_source":"SCTNB","tweeter_id":"314498013","geo":{"lt":60.10867,"ln":-113.64258,"country":"CA"},"followers":1150},"tweet_id":"837783727384236033"},{"url":"http:\/\/twitter.com\/queizan\/statuses\/837792847076130816","license":"gnip","rt":["JCO_ASCO"],"citation_ids":[16842712],"posted_on":"2017-03-03T22:32:34+00:00","author":{"name":"Dr. Jos\u00e9 A. Queiz\u00e1n","image":"https:\/\/pbs.twimg.com\/profile_images\/805313113016799232\/jBSTAjA7_normal.jpg","description":"Medico Especialista en Hematologia y Hemoterapia","id_on_source":"queizan","tweeter_id":"2334315479","geo":{"lt":null,"ln":null},"followers":403},"tweet_id":"837792847076130816"},{"url":"http:\/\/twitter.com\/queizan\/statuses\/838365708048351232","license":"gnip","rt":["timfenske"],"citation_ids":[16842712],"posted_on":"2017-03-05T12:28:55+00:00","author":{"name":"Dr. Jos\u00e9 A. Queiz\u00e1n","image":"https:\/\/pbs.twimg.com\/profile_images\/805313113016799232\/jBSTAjA7_normal.jpg","description":"Medico Especialista en Hematologia y Hemoterapia","id_on_source":"queizan","tweeter_id":"2334315479","geo":{"lt":null,"ln":null},"followers":403},"tweet_id":"838365708048351232"},{"url":"http:\/\/twitter.com\/HemSandoval\/statuses\/838504752098988032","license":"gnip","rt":["timfenske"],"citation_ids":[16842712],"posted_on":"2017-03-05T21:41:26+00:00","author":{"name":"Jose Sandoval S, MD","image":"https:\/\/pbs.twimg.com\/profile_images\/753775338958848001\/fHwZjW2c_normal.jpg","id_on_source":"HemSandoval","tweeter_id":"4067920889","geo":{"lt":27.94752,"ln":-82.45843,"country":"US"},"followers":108},"tweet_id":"838504752098988032"},{"url":"http:\/\/twitter.com\/FrancescoTurtu1\/statuses\/838764578657951745","license":"gnip","citation_ids":[16842712],"posted_on":"2017-03-06T14:53:53+00:00","author":{"name":"Francesco Turturro","url":"http:\/\/faculty.mdanderson.org\/Francesco_Turturro\/Default.asp?SNID=1484660469","image":"https:\/\/pbs.twimg.com\/profile_images\/763530448618217472\/8el8ozjZ_normal.jpg","description":"Lymphoma specialist expressing his own opinions","id_on_source":"FrancescoTurtu1","tweeter_id":"1191609930","geo":{"lt":29.76328,"ln":-95.36327,"country":"US"},"followers":968},"tweet_id":"838764578657951745"},{"url":"http:\/\/twitter.com\/AndreGoyMD\/statuses\/839215330178129921","license":"gnip","citation_ids":[16842712],"posted_on":"2017-03-07T20:45:01+00:00","author":{"name":"Dr. Andre Goy","url":"http:\/\/www.jtcancercenter.org\/physician\/andre-goy\/","image":"https:\/\/pbs.twimg.com\/profile_images\/664112200064172032\/a48t2J7I_normal.jpg","description":"Chairman and Director of @JTCancerCenter @HackensackUMC and Chief of Lymphoma","id_on_source":"AndreGoyMD","tweeter_id":"73166720","geo":{"lt":40.88593,"ln":-74.04347,"country":"US"},"followers":663},"tweet_id":"839215330178129921"},{"url":"http:\/\/twitter.com\/suepomp\/statuses\/839428589518999556","license":"gnip","rt":["AndreGoyMD"],"citation_ids":[16842712],"posted_on":"2017-03-08T10:52:26+00:00","author":{"name":"Susan Pomponio","image":"https:\/\/pbs.twimg.com\/profile_images\/378800000818240473\/cdce5f83b91b18958f3207a3eb295422_normal.jpeg","id_on_source":"suepomp","tweeter_id":"1248925712","geo":{"lt":null,"ln":null},"followers":94},"tweet_id":"839428589518999556"},{"url":"http:\/\/twitter.com\/JediPD\/statuses\/839833832035602432","license":"gnip","citation_ids":[16842712],"posted_on":"2017-03-09T13:42:43+00:00","author":{"name":"Parvez Dara MD, MBA","url":"http:\/\/jedismedicine.blogspot.com","image":"https:\/\/pbs.twimg.com\/profile_images\/3159464877\/50f678ee4f79a27f917462f8637cccf5_normal.jpeg","description":"Parvez Dara is a Physician (Medical Hematologist-Oncologist), Pilot, Author, Educator, Husband, Father and Student","id_on_source":"JediPD","tweeter_id":"16132457","geo":{"lt":40.16706,"ln":-74.49987,"country":"US"},"followers":3795},"tweet_id":"839833832035602432"},{"url":"http:\/\/twitter.com\/timfenske\/statuses\/857952569846624258","license":"gnip","citation_ids":[16842712],"posted_on":"2017-04-28T13:40:07+00:00","author":{"name":"Tim Fenske","url":"http:\/\/www.mcw.edu\/Hemonc\/faculty\/TimothyFenske.htm","image":"https:\/\/pbs.twimg.com\/profile_images\/771499184356597760\/9KxTNJAO_normal.jpg","description":"Lymphoma, Malignant Hematology, Drug Development, Blood and Marrow Transplantation, and other medical news & views.","id_on_source":"timfenske","tweeter_id":"1036403696","geo":{"lt":43.0389,"ln":-87.90647,"country":"US"},"followers":1566},"tweet_id":"857952569846624258"}],"news":[{"title":"Late Relapse of Classical Hodgkin Lymphoma in German Hodgkin Study Group Trials","url":"http:\/\/ct.moreover.com\/?a=30657630163&p=1pl&v=1&x=FmfYJB9tViMhpe1sIFNJqQ","license":"public","citation_ids":[16842712],"posted_on":"2017-05-22T22:11:19+00:00","summary":"By Matthew Stenger Posted: 3\/8\/2017 9:40:19 AM Last Updated: 3\/8\/2017 9:40:19 AM Tweet this page Advertisement In patients with classical Hodgkin lymphoma, the 15-year cumulative incidence of late relapse was 6.9%.","author":{"name":"The ASCO Post","url":"http:\/\/www.ascopost.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/496\/normal\/Screen_Shot_2016-02-03_at_09.24.05.png?1454491455"}}]}}